Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Tumor classification based on their predicted responses to kinase inhibitors is a major goal for advancing targeted personalized therapies. Here, we used a phosphoproteomic approach to investigate biological heterogeneity across hematological cancer cell lines including acute myeloid leukemia, lymphoma, and multiple myeloma. Results: Mass spectrometry was used to quantify 2,000 phosphorylation sites across three acute myeloid leukemia, three lymphoma, and three multiple myeloma cell lines in six biological replicates. The intensities of the phosphorylation sites grouped these cancer cell lines according to their tumor type. In addition, a phosphoproteomic analysis of seven acute myeloid leukemia cell lines revealed a battery of phosphorylation sites whose combined intensities correlated with the growth-inhibitory responses to three kinase inhibitors with remarkable correlation coefficients and fold changes (> 100 between the most resistant and sensitive cells). Modeling based on regression analysis indicated that a subset of phosphorylation sites could be used to predict response to the tested drugs. Quantitative analysis of phosphorylation motifs indicated that resistant and sensitive cells differed in their patterns of kinase activities, but, interestingly, phosphorylations correlating with responses were not on members of the pathway being targeted; instead, these mainly were on parallel kinase pathways. Conclusion: This study reveals that the information on kinase activation encoded in phosphoproteomics data correlates remarkably well with the phenotypic responses of cancer cells to compounds that target kinase signaling and could be useful for the identification of novel markers of resistance or sensitivity to drugs that target the signaling network.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788 · cited 1×
“However, protein, gene, or mRNA studies do not necessarily reflect enzyme activity, which ultimately determines the activation status of signaling pathways involved in cancer cell biology [5,6,47,48].”
BackgroundThe Proteomics Identifications (PRIDE) database and associated tools: status in 2013
Vizcaíno, J. A., Côté, R. G., Csordas, A., Dianes, J. A., Fabregat, A., Foster, J. M., Griss, J., Alpi, E., Birim, M., Contell, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1262 · Cited by 1,918
Comparing protein abundance and mRNA expression levels on a genomic scale
Greenbaum, D. (2003) · Genome biology · doi:10.1186/gb-2003-4-9-117 · Cited by 1,692 · cited 2×
“Although gene expression signatures can be used to classify malignancies into subgroups [2-4], a system-level understanding of the biochemical pathways (both signaling and metabolic) responsible for tumor phenotypes requires knowledge of signaling pathway activity, information that cannot be provided by measuring mRNA…”
BackgroundMammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E
Fingar, D. C., Salama, S., Tsou, C., Harlow, E., & Blenis, J. (2002) · Genes & Development · doi:10.1101/gad.995802 · Cited by 1,093 · cited 2×
“Phosphorylation sites on 4EBP1 (gene name EIF4EBP1) or Ribosomal S6 (gene name RPS6), which are known to be downstream of PI3K/mTOR(Ref [36]), did not correlate with the responses of our cancer cell panel to the PI3K/mTOR inhibitor PI-103 (Figure 7A).”
ResultHsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., et al. (2011) · Science · doi:10.1126/science.1199498 · Cited by 1,084
Geiger, T., Wehner, A., Schaab, C., Cox, J., & Mann, M. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014050 · Cited by 797 · cited 1×
“Label-free approaches are preferred when the aim is to compare large sample numbers and replicates [26,27] even though the penetrance of the approach may not be as large as when using techniques that allow extensive fractionation before mass spectrometry analysis.”
Method
Cited by
Phosphoproteomics in the Age of Rapid and Deep Proteome Profiling
Riley, N. M., & Coon, J. J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b04123 · Cited by 265
Integrative proteogenomic characterization of early esophageal cancer
Li, L., Jiang, D., Zhang, Q., Liu, H., Xu, F., Guo, C., Qin, Z., Wang, H., Feng, J., Liu, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37440-w · Cited by 67
A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis
Basak, I., Wicky, H. E., McDonald, K. O., Xu, J. B., Palmer, J. E., Best, H. L., Lefrancois, S., Lee, S. Y., Schoderboeck, L., & Hughes, S. M. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03813-x · Cited by 32
“Phosphosite.org (https:// www. phosp hosite. org/ prote inAct ion. action? id= 36414 03& showA llSit es= true, accessed 8/5/2020) lists three ubiquitylation sites: K65 [62], K105 [62–64] and K215 [65], as well as one phosphorylation site on T283 [66] (Fig.”
BackgroundGlobal phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas
Rolland, D., Basrur, V., Conlon, K., Wolfe, T., Fermin, D., Nesvizhskii, A. I., Lim, M. S., & Elenitoba-Johnson, K. S. J. (2014) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.01.036 · Cited by 31
Integrative proteomic characterization of trace FFPE samples in early-stage gastrointestinal cancer
(2022) · doi:10.1186/s12953-022-00188-0 · Cited by 4
Metadata
- Authors
- Casado, P., Alcolea, M. P., Iorio, F., Rodríguez-Prados, J.-C., Vanhaesebroeck, B., Saez-Rodriguez, J., Joel, S., & Cutillas, P. R.
- Venue
- Genome Biology
- Published
- 2013-04-29
- Volume
- 14
- Issue
- 4
- Pages
- R37-R37
- ISSN
- 1465-6906 (ISSN-L)
- 1474-760X
- OpenAlex
- W2118483584
- Cited by
- 82
- References
- 6
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. https://app.cochat.ai/papers/10.1186/gb-2013-14-4-r37
- The paper
- Casado, P., Alcolea, M. P., Iorio, F., Rodríguez-Prados, J.-C., Vanhaesebroeck, B., Saez-Rodriguez, J., Joel, S., & Cutillas, P. R. (2013). Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biology. https://doi.org/10.1186/gb-2013-14-4-r37
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.